Synthesis of Chlorosunitinib Analogs as Novel Antiangiogenic Anticancer Agents

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會 > Item 310902800/24238

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/24238

標題:	Synthesis of Chlorosunitinib Analogs as Novel Antiangiogenic Anticancer Agents
作者:	Li-Chiu Lin (林利秋) Wen-Hsin Huang (黃文鑫) An-Rong Lee (李安榮)
日期:	2011
上傳時間:	2011-06-23 14:57:26 (UTC+8)
摘要:	Current cancer therapeutics is surgery, radiotherapy, chemotherapy and target therapy. Today cancer is a more treatable disease than at any time in the past. But cancer treatment is still far from ideal due to many cancers not be cured. Anti-angiogenesis, me of targeted cancer therapies, possessing highly specificity and selectivity for cancer cells and lower toxicity for normal cells, is a novel development of milestone in cancer therapy. Drugs with anti-lgiogenic properties such as sunitinib (Sutent) and sorafenib (Nexavar) have been shown to be useful against cancers. Sunitinib is one of the small-molecule drugs for the treatment of cancer with GIST and RCC. It's a multiple tyrosine kinase inhibitor, which competes with the ATP-binding sites within the tyrosine kinase receptors to prevent angiogenesis and tumor formation. For the reason that lots of anti-cancer drugs have resistance to anti-angiogenic therapy, the finding of new anti-angiogenic agents with higher therapeutic efficacy, lower toxicity and minor drug resissistance is a hot task to be resolved. In search of better drugs, the potent anti-angiogenic anticancer agents are in active progress in our laboratories. Modification of pyrrole ring of sunitinib which inhibit PDGF-, Kit-, and VEGF-mediated signaling is conducted. Current preliminary r screening of experiments on inhibition of tube formation were conducted in triplicate in 24-multiwell dishes, cultured with HUVECs co-cultured with human fibroblasts, using angiogenesis kit (Kurabo, Okayama, Japan), according to the manufacturer's instruction. The area and tube length were measured quantitatively with the Kurabo angiogenesis image analyzer (Kurabo, Okayama, Japan) in five different fields per well, and analyzed statistically. Further structural modification and optimization of target compounds and study of structure-activity relationships are in progress.
關聯:	2011年台俄有機、藥物與生物化學交流暨藥物化學研討會，起迄日：2011/04/06~2011/04/05，地點：溪頭台大實驗林
显示于类别:	[藥理學院] 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會

文件中的档案:

档案	描述	大小	格式	浏览次数
pp-22.pdf		87Kb	Adobe PDF	419	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....